Targeted Treatments for p53 Deficiency

Rezatapopt, developed by PMV Pharmaceuticals, Inc., is a small molecule designed to address a specific p53 Y220C mutation – one of the few cases where a single amino acid change creates a new, druggable pocket. It was discovered through a structure-based medicinal chemistry campaign starting from known fragment-like binders, followed by iterative SAR and crystallography-guided optimization. Instead of blocking activity, the compound binds this mutation-induced cavity and stabilizes the native fold of p53, restoring its normal tumor-suppressor function. Fluorine-driven stereochemistry improved both binding geometry – by reinforcing the Thr150 contact – and drug-like behavior, raising permeability and exposure enough to achieve strong tumor regression in vivo. For me, this is a clear example of structure-based design advancing beyond inhibition and toward restoring function in disease-relevant proteins. It reflects the kind of complex, precision-level challenge that modern computational design approaches are increasingly able to address. #pharma #drugdiscovery #oncology

From 9.7 μM to 56 nM: How structure-guided design rescued a "loss-of-function" oncogenic mutant. Targeting the p53-Y220C mutant pocket requires precise molecular tailoring. This recent study in JMC beautifully highlights how the authors optimized the classic lead, achieving a massive ~170-fold increase in binding affinity with the indole-based candidate D2. ➔ Targeting the Hydrophobic Cavity: The core morphing to a substituted indole featuring -CF3 allowed for deep, optimal engagement within the mutation-induced hydrophobic cavity. ➔ Reaching the Solvent Regions: Appending polar moieties (N-methylpiperidine & the methoxy-methylsulfonyl benzene) extended the molecule out into the surrounding solvent regions, optimizing electrostatic interactions and improving solubility. ➔ Thermal Stabilization: This precise spatial fit enhanced the thermodynamic stability of the mutant protein and restored p53-dependent downstream transcriptional activity. 👍D2 translated this affinity into potent growth inhibition across Y220C-mutant cell lines and achieved 59% tumor growth inhibition in a xenograft model. Article https://lnkd.in/eiPa9wvY #MedicinalChemistry #StructureBasedDesign #p53 #Oncology

p53 gene mutations shows up in half of all cancers. it has been a known drug target for 35 years. and until this week, nobody had a drug that worked. this week, PMV Pharma - a company that has been working on a single p53 mutation since 2013 - published phase 1 data in the NEJM. 20% overall response rate in patients with no other options left. here's why it took 35 years: p53 is mutated in ~50% of all cancers. but "mutated" covers thousands of different variants. most drug programs went after the degradation pathway - keep p53 from getting destroyed. phase 3 after phase 3 failed, cancer finds other ways to deactivate. PMV's bet was different. the Y220C mutation exposes a specific hydrophobic pocket in the p53 protein. Rezatapopt fits into that pocket and refolds the protein back toward its wildtype shape. it's not preventing degradation. it's fixing the structure directly. that only works on Y220C specifically. but Y220C shows up in ~1% of all solid tumors - which at global cancer scale is a large patient population. the open question is resistance. cancers are under enormous selective pressure to kill p53 function. there are >1,000 ways to do it. MDM2 overexpression, secondary mutations, alternate pathway rewiring. the drug works. whether it keeps working will be the real trial. but 20% objective response rate in heavily pretreated patients is real signal. and it joins Sotorasib and Adagrasib — the first approved RAS inhibitors — as proof that the "undruggable" label in oncology might have an expiration date.

🚨 p53 is the most mutated gene in cancer… but still NO approved reactivator. That may finally be changing. A new wave of mutation-specific p53 reactivation is showing real clinical signal 👇 🧬 Why this matters ~50% cancers harbor TP53 mutations Tumor suppressors need restoration, not inhibition → historically “undruggable” 💊 The shift: precision reactivation Old approach ❌ “one-size-fits-all” (APR-246) → weak activity New approach ✅ mutation-specific targeting 👉 Rezatapopt (PC14586) Targets Y220C p53 pocket → refolds mutant protein 📊 PYNNACLE trial • ORR: 19.7% (14/71) • KRAS WT: 30.4% • KRAS mutant: 0% • Grade 3–4 AEs: ~50%, no grade 5 📌 Biology-driven selection = real signal 🧠 Big shift Not all p53 mutations are equal → Structural mutants can be rescued → Needs mutation-specific drugs + basket trials 🎯 Takeaway We are entering: 👉 Targeted therapy for tumor suppressors 👉 Ultra-precise oncology 🔖 Save this: p53 is back 📖 Full paper in comment ⬇️

They concluded: The resulting bifunctional molecule promotes formation of a p53Y220C–PLK1 ternary complex, mislocalizes PLK1, inhibits PLK1 activity, elicits selective G2/M arrest and induces apoptosis in TP53Y220C cells while sparing wild-type TP53 cells. These data exemplify a potentially generalizable framework for targeting TP53 missense mutations by leveraging mutant p53 protein abundance to induce cell death, independent of p53’s transcriptional activity.

We can now activate #p53 Y220C with small molecules! #TRAP1 TP53 is the most commonly mutated gene in cancer, yet therapeutic reactivation of mutant p53 has remained one of the major challenges in oncology drug discovery. In this study, we describe #TRAP-1 — TRanscriptional Activator of p53 — a small-molecule chemical inducer of proximity that brings together p53-Y220C and BRD4 in a ternary complex. This proximity-based mechanism potently activates mutant p53 and drives robust transcription of p53 target genes, including CDKN1A, which induces cellular senescence and apoptosis. Fun collaboration with Nathanael Gray & Laura Attardi labs Xijun Zhu and Woong Sub Byun and Dominika Pieńkowska & Jan Gerhartz from team #Bonn. Read more: https://lnkd.in/eMA5NNsg #p53 #TP53 #CancerResearch #ChemicalBiology #InducedProximity #DrugDiscovery #TargetedTherapy #Oncology